131 related articles for article (PubMed ID: 38832095)
1. Study protocol: A randomized, double-blind, placebo-controlled trial of isavuconazole prophylaxis for the prevention of covid-19-associated pulmonary aspergillosis.
Jenks JD; Hoenigl M; Thompson GR
Contemp Clin Trials Commun; 2024 Jun; 39():101310. PubMed ID: 38832095
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. [Expert consensus on diagnosis and treatment of severe COVID-19 associated pulmonary
;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jan; 47(1):10-23. PubMed ID: 38062689
[TBL] [Abstract][Full Text] [Related]
4. Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study.
Hatzl S; Reisinger AC; Posch F; Prattes J; Stradner M; Pilz S; Eller P; Schoerghuber M; Toller W; Gorkiewicz G; Metnitz P; Rief M; Prüller F; Rosenkranz AR; Valentin T; Krause R; Hoenigl M; Schilcher G
Crit Care; 2021 Sep; 25(1):335. PubMed ID: 34526087
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit: Impact of Antifungal Prophylaxis.
Frost J; Gornicec M; Reisinger AC; Eller P; Hoenigl M; Prattes J
Mycopathologia; 2024 Jan; 189(1):3. PubMed ID: 38217742
[TBL] [Abstract][Full Text] [Related]
6. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
8. COVID-19-Associated Pulmonary Aspergillosis (CAPA).
Dimopoulos G; Almyroudi MP; Myrianthefs P; Rello J
J Intensive Med; 2021 Oct; 1(2):71-80. PubMed ID: 36785564
[TBL] [Abstract][Full Text] [Related]
9. Nebulized Amphotericin B in Mechanically Ventilated COVID-19 Patients to Prevent Invasive Pulmonary Aspergillosis: A Retrospective Cohort Study.
Melchers M; van Zanten ARH; Heusinkveld M; Leeuwis JW; Schellaars R; Lammers HJW; Kreemer FJ; Haas PJ; Verweij PE; van Bree SHW
Crit Care Explor; 2022 May; 4(5):e0696. PubMed ID: 35558738
[TBL] [Abstract][Full Text] [Related]
10. Antifungal prophylaxis with nebulized amphotericin-B in solid-organ transplant recipients with severe COVID-19: a retrospective observational study.
Rombauts A; Bodro M; Daniel Gumucio V; Carbonell I; Favà À; Lladó L; González-Costello J; Oppenheimer F; Castel-Lavilla MÁ; Len O; Marquez-Algaba E; Nuvials-Casals X; Martínez González D; Lacasa JS; Carratalà J; Sabé N
Front Cell Infect Microbiol; 2023; 13():1165236. PubMed ID: 37180450
[TBL] [Abstract][Full Text] [Related]
11. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study.
Feys S; Gonçalves SM; Khan M; Choi S; Boeckx B; Chatelain D; Cunha C; Debaveye Y; Hermans G; Hertoghs M; Humblet-Baron S; Jacobs C; Lagrou K; Marcelis L; Maizel J; Meersseman P; Nyga R; Seldeslachts L; Starick MR; Thevissen K; Vandenbriele C; Vanderbeke L; Vande Velde G; Van Regenmortel N; Vanstapel A; Vanmassenhove S; Wilmer A; Van De Veerdonk FL; De Hertogh G; Mombaerts P; Lambrechts D; Carvalho A; Van Weyenbergh J; Wauters J
Lancet Respir Med; 2022 Dec; 10(12):1147-1159. PubMed ID: 36029799
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole for COVID-19-Associated Invasive Mold Infections.
Ullah N; Sepulcri C; Mikulska M
J Fungi (Basel); 2022 Jun; 8(7):. PubMed ID: 35887431
[TBL] [Abstract][Full Text] [Related]
13. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Antifungal Prophylaxis for COVID-19 Associated Pulmonary Aspergillosis.
Hawes AM; Permpalung N
Antibiotics (Basel); 2022 Nov; 11(12):. PubMed ID: 36551361
[TBL] [Abstract][Full Text] [Related]
15. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial.
Grau-Pujol B; Camprubí D; Marti-Soler H; Fernández-Pardos M; Guinovart C; Muñoz J
Trials; 2020 Jul; 21(1):688. PubMed ID: 32727613
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.
Kohno S; Izumikawa K; Takazono T; Miyazaki T; Yoshida M; Kamei K; Ogawa K; Taniguchi S; Akashi K; Tateda K; Mukae H; Miyazaki Y; Okada F; Kanda Y; Kakeya H; Suzuki J; Kimura SI; Kishida M; Matsuda M; Niki Y
J Infect Chemother; 2023 Feb; 29(2):163-170. PubMed ID: 36307059
[TBL] [Abstract][Full Text] [Related]
18. Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity.
Machado M; Valerio M; Álvarez-Uría A; Olmedo M; Veintimilla C; Padilla B; De la Villa S; Guinea J; Escribano P; Ruiz-Serrano MJ; Reigadas E; Alonso R; Guerrero JE; Hortal J; Bouza E; Muñoz P;
Mycoses; 2021 Feb; 64(2):132-143. PubMed ID: 33210776
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M
Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395
[TBL] [Abstract][Full Text] [Related]
20. COVID-19-associated pulmonary aspergillosis (CAPA) in hematological patients: Could antifungal prophylaxis be necessary? A nationwide study.
Tamayo-Velasco Á; López-Herrero R; Gómez-García LM; Sánchez-de Prada L; Aguilar-Monserrate G; Martín-Fernández M; Bardají-Carrillo M; Álvaro-Meca A; Tamayo E; Resino S; Miramontes-González JP; Peñarrubia-Ponce MJ
J Infect Public Health; 2024 Jun; 17(6):939-946. PubMed ID: 38613930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
